Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 14/20 | 0.63 |
| ▸ | CHUK | O15111 | 14/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CIT | O14578 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 5/20 | 0.43 |
| ▸ | CASP3 | P42574 | 3/20 | 0.43 |
| ▸ | CASP7 | P55210 | 3/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3418145 | 0.87 | IKBKB (0.66) | IKBKBCHUKCYP2C9CITCDK9 | |
| SCHEMBL13505174 | 0.86 | IKBKB (0.74) | IKBKBCHUKCYP2C9CITCDK9 | |
| SCHEMBL3413149 | 0.85 | IKBKB (0.73) | IKBKBCHUKCYP2C9CITCDK9 | |
| SCHEMBL3617126 | 0.82 | IKBKB (0.68) | IKBKBCHUKCYP2C9CITCDK9 | |
| SCHEMBL3415201 | 0.81 | IKBKB (0.65) | IKBKBCHUKCYP2C9CITCDK9 | |
| Trifluoroacetic Acid SCHEMBL3413145 | 0.79 | IKBKB (0.85) | IKBKBCHUKCYP2C9CITCDK9 | |
| SCHEMBL3418229 | 0.79 | IKBKB (0.73) | IKBKBCHUKCYP2C9CITCDK9 | |
| SCHEMBL3412911 | 0.78 | IKBKB (1.00) | IKBKBCHUKCYP2C9CITCDK9 | |
| Trifluoroacetic Acid SCHEMBL3415206 | 0.77 | IKBKB (0.67) | IKBKBCHUKCYP2C9CITCDK9 | |
| SCHEMBL2989332 | 0.77 | IKBKB (0.51) | IKBKBCHUKCIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176891-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| US-20080146606-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176891-A1 | NOVEL COMPOUNDS | NFKBIA, IKBKG, IKBKE | IKBKB 4/4885CHUK 8/4885CYP2C9 3454/4885 |
| US-20080146606-A1 | NOVEL COMPOUNDS | NFKBIA, IKBKG, IKBKE | IKBKB 4/4885CHUK 8/4885CYP2C9 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.